Aptadel Therapeutics is a preclinical-stage biotech company based in Barcelona, Spain with a strong focus on developing cancer treatments utilizing aptamer technology. The company's lead indication is Ewing Sarcoma, a rare form of bone cancer primarily affecting children. Established in 2020, Aptadel Therapeutics recently received a €1.70M investment in a Seed Round, with Alba Pérez Foundation being the lead investor, marking a significant milestone. This biotech startup operates in the Biotechnology and Health Care industries with a goal to revolutionize cancer treatment through its RNA-based delivery platform. With its innovative approach and dedicated team, Aptadel Therapeutics stands at the forefront of the biotech sector, aiming to make a positive impact on cancer therapy.
No recent news or press coverage available for Aptadel Therapeutics.